Shivi Jain

I am a hematologist with focus in Plasma cell disorders. My posts are my opinion.

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Phase 3 CEPHEUS study of Dara+VRd vs. VRd finds MRD-negativity 60.9% for quad vs. 39.4% w/ VRd; ≥CR rates 81.2% vs. 61.6%; sustained MRD negativity (≥12 mos) 48.7% vs. 26.3%, giving 43% lower progression or death risk: https://t.co/42vj4aZyq7. #mmsm

[Marcus Pinto, MD, MS @MarcusVPinto]

Amyloid neuropathies are treatable and should not be missed. @gabifpucci and I updated the @neudrawlogy amyloid neuropathy infographic and tweetorial that I share below.

Remember that amyloid neuropathy is one of the causes of rapidly progressive neuropathy and that's why you must order serum SPEP/immunofixation, free light chains, and fat aspirate in all these patients and consider a nerve biopsy If rest of work up is inconclusive.

1/x

[Muzaffar Qazilbash @Transplant_Doc]

Isa-KRd x 6 cycles Induction in NDMM: MIDAS Trial. N=791, VGPR 91%, MRD- 10-5 63%, MRD 10-6 47%, median CD34 collection: 7 x 10e6/kg @PerrotAurore https://t.co/sIjyIMEaYs #mmsm #bmtsm @BloodJournal

[Robin Tuohy @IMFsupport]

Thank you @UrviShahMD for this important research! Patients and Care Partners really appreciate this! #ASH24 #IMFASH24 #MMsm

[Shivi Jain @shivijain80]

#ASH24 great talk by @RahulBanerjeeMD hopefully elimination of 24hr UPEP for follow up in MM will become a much needed practice change! No more urine in the fridge

[Ben Derman @bdermanmd]

PERSEUS MRD Data:
Maintenance upgraded MRD(-) responses up to 2-3 years later, and appears to be more profound with Dara-R maintenance.
Dara-VRd/Dara-R doubled chances of reaching MRD negativity & sustaining it.
I am more convinced of benefit of dara as part of maintenance
#mmsm

[Manni Mohyuddin @ManniMD1]

Suggested approach to 1st relapse of myeloma post #ASCO24

Its suddenly more complicated-and bispecifics will change this too.

Bela based triplets >> Dara/Bort/Dex, but CD38+Carfil/Dex still great.

Safety of cilta-cel remains in Q, hard to broadly recommend for now.

#mmsm

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

🚨 Out now DREAMM-7 from NEJM
BVd vs DVd @NEJM
Full disclosure: I am a co-author
🧵 BVd vs DVd in early relapse myeloma:
N=494 (BVd, n=243; DVd, n=251)
Median follow-up 28.2 months 
Median Age: 65
High risk cytogenetics: 17%
EMD: 5% vs 10%
mLOT: 1
Prior dara 1% vs 2%
PI refractory: 9% vs 10%
IMiDs refractory : 39% vs 41%
Lenalidomide refractory: 33% vs 35%
 https://t.co/K11DfYOwk3

#mmsm #myeloma #MedEd #medtwitter #USMIRC #Oncology @oncoalert #ASCO24 @USMIRCNEWS

[John Joseph Strouse @dukesickle]

Final results of Spartan single arm trial of crizanlizumab for secondary prevention of priapism in SCD. Reduced median episodes by 46% #ASH2023 #scd

[Shivi Jain @shivijain80]

@jkw4444 @nascc_org Big day for SCD community #ASH2023

[Julie Kanter @jkw4444]

A much overdue great day for people with #sicklecelldisease. Now we need to implement these treatments. Safely. Efficiently. Ethically. Equally.
@nascc_org will be here to help!

https://t.co/ZseZkLrQBV

[Seethal Jacob, MD, MS @seethal_jacobmd]

Exactly this 👇🏽.

#fixthesystem #sicklecelldisease #accesstocare

[Seethal Jacob, MD, MS @seethal_jacobmd]

👏🏽 Dr. Courtney Fitzhugh for pointing out there is no data that #hydroxyurea increases risk of malignancy compared to those not taking, and the benefits are so great, should not be withheld from patients w/ #sicklecell

[Shivi Jain @shivijain80]

@seethal_jacobmd @jkw4444 Amazing would love to learn more

[Shivi Jain @shivijain80]

@hiba_narvel @HemOncWomenDocs @HemOncFellows Thank you for your support!

[Shivi Jain @shivijain80]

@jkw4444 @RushMedical @SCDAIllinois @chicagosmayor @RushCancer @RushHemOnc Thankyou for gracing the occasion with your presence. This is a milestone for us and we are honored by your presence and support

[Shivi Jain @shivijain80]

1st Annual Sickle Cell Disease Consortium, thank you to everyone who helped make it a success. @jkw4444 @RushMedical @SCDAIllinois @chicagosmayor @RushCancer @RushHemOnc

[P. Venugopal @pvenugop]

Dr. Shivi Jain from Rush University Medical Center speaking at the first Sickle Cell Consortium meeting that she has organized at Chicago today along with her esteemed colleagues.

[Shivi Jain @shivijain80]

@jkw4444 @SCDAIllinois Thank you Dr. Kanter @jkw4444

[Julie Kanter @jkw4444]

Great turnout for #SickleCell @SCDAIllinois @shivijain80